@CoyaTx Coya Therapeutics

Coya Therapeutics posts on X about $coya, ceo, $rdy, in the the most. They currently have [-----] followers and [---] posts still getting attention that total [--] engagements in the last [--] hours.

Engagements: [--] #

• [--] Week [---] -32%
• [--] Month [-----] +159%
• [--] Months [-----] +43%
• [--] Year [------] +45%

Mentions: [--] #

• [--] Week [--] no change
• [--] Month [--] +200%
• [--] Months [--] +29%
• [--] Year [--] +107%

Followers: [-----] #

• [--] Week [-----] -0.05%
• [--] Month [-----] -0.16%
• [--] Months [-----] +1.50%
• [--] Year [-----] +1.10%

CreatorRank: [---------] #

Social Influence

Social category influence stocks 59% countries 7% finance 6% travel destinations 5%

Social topic influence $coya #1, ceo 15%, $rdy 9%, in the 6%, health 5%, science 4%, financial 4%, canada 3%, momentum 3%, we are 2%

Top accounts mentioned or mentioned by @drreddys @alsassociation @familialals @schwabnetwork @innomaphou @methodisthosp @alzassociation @gatesfoundation @nihaging @pharmavoice @loubasenese @alsnewstoday @healioneurology @solomonswisdom @nfl @insidepm @chrisleidli @alzfdn @drreddyss @benzingas

Top assets mentioned Coya Therapeutics, Inc. (COYA) Dr. Reddy's Laboratories Limited American Depositary Shares (RDY) GLP1 (GLP1)

Top Social Posts

Top posts by engagements in the last [--] hours

"Coya today announced the acceptance of the clinical trial application from Health Canada to proceed with the COYA [---] ALSTARS trial for #ALS. This allows for initiation of patient enrollment in the ALSTARS Trial at Canadian ALS centers. For more details: https://www.businesswire.com/news/home/20251223853357/en/Coya-Therapeutics-Receives-Clinical-Trial-Application-CTA-Acceptance-from-Health-Canada-to-Proceed-with-the-COYA-302-ALSTARS-Trial-for-the-Treatment-of-Amyotrophic-Lateral-Sclerosis-ALS"
X Link 2025-12-23T16:05Z [----] followers, [---] engagements

"Thank you to Steve Bryson Ph.D. of @ALSNewsToday for covering an important milestone for Coya Therapeutics. As highlighted in the article Health Canada has issued a No Objection Letter allowing the Phase [--] ALSTARS trial of COYA [---] in ALS to expand into Canada broadening access to this ongoing study. The ALSTARS trial plans to enroll [---] participants across [--] sites through [----]. We look forward to collaborating with Canadian ALS centers as this important study continues. Read the article here: $COYA #ALS #EndALS #Neurodegeneration"
X Link 2026-01-19T21:00Z [----] followers, [---] engagements

"Coya Therapeutics CEO Arun Swaminathan Ph.D. today issued a letter to stockholders. Coya enters [----] with strong momentum and a clear sense of purpose. I believe we are exceptionally well positioned to advance our mission of delivering potentially transformational therapies for patients suffering from devastating neurodegenerative diseases said Dr. Swaminathan. Read the letter here: https://www.businesswire.com/news/home/20260120977124/en/Coya-Therapeutics-CEO-Dr.-Arun-Swaminathan-Issues-Letter-to-Stockholders https://twitter.com/i/web/status/2013601777438867561"
X Link 2026-01-20T13:17Z [----] followers, [---] engagements

"Robert Herpen of @HealioNeurology recently highlighted the FDAs acceptance of Coya Therapeutics IND application for COYA [---] in frontotemporal dementia (#FTD). FTD is a rare progressive #neurodegenerative disease with no approved treatment options. The FDAs acceptance of the IND enables Coya to initiate a clinical trial of COYA [---] an investigational combination therapy designed to address key inflammatory pathways involved in disease progression. Read the article here: #Neurology #ClinicalTrials #Biotech #FrontotemporalDementia"
X Link 2026-01-27T18:09Z [----] followers, [---] engagements

"Coyas President & CMO Dr. Fred Grossman and VP of Patient Advocacy @FamilialALS are on the ground at #SuperBowlLX Radio Row joining @SolomonsWisdom to discuss how Coya is advancing a new treatment approach for #ALS. Former @NFL players have played a powerful role in raising awareness around ALS. Notable voices such as Steve Gleason Tim Green and Dwight Clark have courageously shared their journeys helping shine a national spotlight on the urgent need for research and innovation. Were honored to be part of the conversation and remain committed to advancing science that may meaningfully impact"
X Link 2026-02-02T21:32Z [----] followers, [---] engagements

"CEO Arun Swaminathan PhD recently sat down with Jonathan Grinstein of @Inside_PM for an on-the-ground interview at #JPM26. In the conversation Arun discussed Coyas immune-based approach to #neurodegenerative disease focused on restoring Treg function to address #neuroinflammation in #ALS and #FTD. He also shared insights on early clinical signals in ALS our advancing Phase IIb program and long-term strategic partnerships. Watch the full interview here: https://www.insideprecisionmedicine.com/topics/translational-research/pills-electrodes-viruses-and-tregs-growing-medicines-toolbox/"
X Link 2026-02-03T18:59Z [----] followers, [---] engagements

"Coya Therapeutics will host a live webinar Inside the Evolving ALS Landscape: Biology Innovation and Clinical Progress on Tuesday February [--] [----] at [--] PM ET / [--] PM PT. The discussion will feature leading #ALS experts Dr. Stanley Appel and Dr. James Berry exploring recent scientific advances ongoing challenges in ALS and how innovation in drug development is shaping the future of patient care. The webinar will also highlight Coyas novel immunotherapy approach including COYA [---] and an overview of the ALSTARS Phase [--] clinical trial. Register here: For more details: #EndALS #ClinicalResearch"
X Link 2026-02-10T13:03Z [----] followers, [---] engagements

"Our upcoming #ALS webinar will feature two leading experts whose careers have been dedicated to advancing care and research for people living with ALS: -Stanley Appel MD Chairman Scientific Advisory Board at Coya Therapeutics and Professor of Neurology at Houston Methodist a pioneer in understanding the immune systems role in ALS -James Berry MD MPH Director of the Massachusetts General Hospital Multidisciplinary ALS Clinic nationally recognized for his work improving patient-centered ALS care Moderated by Fred Grossman DO FAPA President & CMO of Coya Therapeutics this conversation will bring"
X Link 2026-02-12T21:51Z [----] followers, [---] engagements

"CEO Arun Swaminathan Ph.D. joined host @ChrisLeidli on the latest episode of #RxforBiotech for a thoughtful conversation on rebalancing the immune system to address #neurodegenerative disease. In the discussion Arun explores Coyas immune-based approach to neurodegenerative diseases including how restoring immune balance and calming inflammation may help meaningfully slow progression in conditions such as #ALS and #Alzheimers disease. Tune in for an insightful conversation on innovation resilience and the future of neurodegenerative disease treatment: https://www.youtube.com/watchv=ASgdnq4BcV8"
X Link 2026-02-13T17:53Z [----] followers, [---] engagements

"November is #AlzheimersAwarenessMonth which provides an important opportunity to heighten awareness about #Alzheimers and show support for the more than 6M Americans currently living with the disease. Learn how you can get involved: @alzfdn #TealforAlz"
X Link 2023-11-03T14:00Z [----] followers, [---] engagements

"Coya & @drreddys have entered into a development and license agreement for the development and commercialization of COYA [---] an investigational combination therapy for the treatment of Amyotrophic Lateral Sclerosis (#ALS). Learn more: $COYA $RDY https://bit.ly/4a4QnbE https://bit.ly/4a4QnbE"
X Link 2023-12-06T14:22Z [----] followers, [---] engagements

"Under the terms of the Agreement Coya has granted @drreddys an exclusive license to commercialize COYA [---] in the United States Canada the European Union and the United Kingdom for amyotrophic lateral sclerosis (#ALS). More info: $COYA $RDY https://bit.ly/4a4QnbE https://bit.ly/4a4QnbE"
X Link 2023-12-06T16:00Z [----] followers, [---] engagements

"Coya retains the right to commercialize COYA [---] for patients with #ALS in Japan Mexico & South America. Coya will have responsibility for the clinical development of COYA [---] & for seeking regulatory approval for patients with ALS in the U.S. $COYA $RDY https://bit.ly/4a4QnbE https://bit.ly/4a4QnbE"
X Link 2023-12-06T16:30Z [----] followers, [---] engagements

".@drreddyss will make a $7.5M upfront payment to Coya additional $4.2M payment upon FDA acceptance of an IND for Coya [---] for ALS and $4.2M upon dosing of the first patient in the first Ph [--] trial. Coya anticipates the IND filing in H1 [----]. $COYA $RDY https://bit.ly/4a4QnbE https://bit.ly/4a4QnbE"
X Link 2023-12-06T19:14Z [----] followers, [---] engagements

"Coya's CEO Dr. Howard Berman comments on the Company's collaboration with Dr. Reddy's for the development and commercialization of COYA [---] for the treatment of Amyotrophic Lateral Sclerosis (#ALS). For more details: $COYA $RDY https://bit.ly/4a4QnbE https://bit.ly/4a4QnbE"
X Link 2023-12-07T15:45Z [----] followers, [---] engagements

"Coya intends to leverage Secretary Rosss extensive experience in both the business and investment community to help guide strategic partnering activities capital markets initiatives and drug development programs. $COYA"
X Link 2023-12-20T16:00Z [----] followers, [---] engagements

"Coya CEO Dr. Howard Berman comments on the Company's successful Pre-IND and Type C Meetings with the FDA to advance the development of COYA [---] for Amyotrophic Lateral Sclerosis (#ALS). Learn more: $COYA"
X Link 2024-01-08T16:15Z [--] followers, [---] engagements

"Dr. Fred Grossman Coyas President and Chief Medical Officer comments on the Company's pipeline expansion of COYA [---] to include #FrontotemporalDementia and #ParkinsonsDisease in addition to #ALS. For more info visit: $COYA"
X Link 2024-01-16T18:00Z [----] followers, [---] engagements

"Coya Therapeutics secures key financing in its fight against #neurodegenerative diseases. CEO Dr. Howard Berman recently joined @Benzingas #AllAccess. If you missed it watch the full interview here: $COYA #Biotech #Science"
X Link 2024-02-06T16:48Z [----] followers, [---] engagements

"Soon on @SchwabNetwork around 10:20am ET: Coyas CEO Dr. Howard Berman and @drreddys CEO of North America Generics Marc Kikuchi will discuss why the treatment of neurodegenerative diseases is at the forefront of our research & more. Stream: $COYA $RDY https://schwabnetwork.com/ https://schwabnetwork.com/"
X Link 2024-02-29T14:00Z [----] followers, [---] engagements

"Tune in Coyas CEO Dr. Howard Berman and @drreddys CEO of North America Generics Marc Kikuchi will be live on @SchwabNetwork around 10:20am ET. Stream here: $COYA $RDY #Biotech"
X Link 2024-02-29T15:00Z [----] followers, [----] engagements

"Coya and Dr. Reddys are investing in the fight against #ALS If you missed the interview on @SchwabNetwork with @OJRenick tune in here: $COYA $RDY #ALSAwareness https://bit.ly/49Oc5iY https://bit.ly/49Oc5iY"
X Link 2024-02-29T20:16Z [----] followers, [---] engagements

"Coya has teamed up with @drreddys to research a treatment for #ALS. Tune into the engaging interview on Schwab Network with CEOs Howard Berman and Marc Kikuchi to learn how this collaboration is revolutionizing standards in ALS treatments $COYA $RDY https://bit.ly/49Oc5iY https://bit.ly/49Oc5iY"
X Link 2024-03-01T16:36Z [----] followers, [---] engagements

"Coya Therapeutics Announces Inclusion in the @MSCI_Inc USA Micro Cap Index starting at market close on May [--]. Read more about the index and Coya's inclusion in our latest press release here: $COYA #Coyatherapeutics https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-Announces-Inclusion-in-the-MSCI-USA-Micro-Cap-Index/default.aspx https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-Announces-Inclusion-in-the-MSCI-USA-Micro-Cap-Index/default.aspx"
X Link 2024-05-28T12:28Z [----] followers, [---] engagements

"Coya was recently included in @InvestorPlace's [--] Biotech Stocks to Put on Your Breakthrough Radar highlighting some of our clinical breakthroughs. Read more in the full article here: $COYA #CoyaTherapeutics #EndALS #ALSAwarenessMonth https://investorplace.com/2024/05/7-biotech-stocks-to-put-on-your-breakthrough-radar/ https://investorplace.com/2024/05/7-biotech-stocks-to-put-on-your-breakthrough-radar/"
X Link 2024-05-28T17:48Z [----] followers, [---] engagements

"CEO Howard Berman was included this week by @InnoMapHou in their Houston innovators to know. Read more about Howard and his reasons for starting Coya here: #CoyaTherapeutics #Innovators #Neurodegenerative #Research https://houston.innovationmap.com/matthew-kuhn-tim-boire-howard-berman-2668692240.html https://houston.innovationmap.com/matthew-kuhn-tim-boire-howard-berman-2668692240.html"
X Link 2024-07-10T13:45Z [----] followers, [---] engagements

"Coya Therapeutics announced that results from a double-blind placebo-controlled study in Alzheimers disease will be presented in October at the Clinical Trials on Alzheimers Disease Conference (CTAD24) in Madrid. Read more in our latest press release: https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-Announces-that-Results-from-a-Double-Blind-Placebo-Controlled-Study-in-Alzheimers-Disease-will-be-presented-on-October-29-2024-at-the-Clinical-Trials-on-Alzheimers-Disease-Conference-CTAD24-in-Madrid/default.aspx"
X Link 2024-08-02T12:30Z [----] followers, [---] engagements

"Coya Therapeutics is a biotech focused on developing new therapies to enhance the function of Tregs and has already shown strong proof of concept data in ALS and Alzheimer's. Learn more about Coya at #CoyaTherapeutics #Tregs #Inflammation #Research http://coyatherapeutics.com http://coyatherapeutics.com"
X Link 2024-08-13T15:25Z [----] followers, [---] engagements

"The immune system protects from invading microorganisms. When it attacks what it's meant to protect it can lead to autoimmune disease. Coya is enhancing the function of Tregs to treat autoimmune disease. Learn more @AutoimmuneAssoc: #AutoImmune #Research https://autoimmune.org/resource-center/about-autoimmunity/ https://autoimmune.org/resource-center/about-autoimmunity/"
X Link 2024-08-15T17:25Z [----] followers, [---] engagements

"NEWS: Coya Therapeutics announces the results of a preclinical model of COYA [---] for the treatment of Parkinson's Disease. Read more in our latest press release: #CoyaTherapeutics #Research #PreClinical #Parkinsons https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-Announces-Subcutaneously-Administered-COYA-302-Elicits-Direct-Anti-Inflammatory-Effect-in-Brain-in-a-Preclinical-Inflammatory-Mouse-Model-of-Parkinsons-Disease/default.aspx"
X Link 2024-09-16T12:27Z [----] followers, [---] engagements

"MAJOR NEWS: Coya Therapeutics announces positive results of a double-blind study of low-dose IL-2 in Alzheimers Disease at CTAD in Madrid co-sponsored with @MethodistHosp @alzassociation @gatesfoundation and @NIHAging. Read the full press release here: $COYA #CoyaTherapeutics #EndALZ #Research https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-Announces-Positive-Results-of-a-Double-Blind-Study-of-Subcutaneous-Low-Dose-Interleukin-2-LD-IL-2-in-Alzheimers-Disease-AD-Presented-at-the-Clinical-Trials-on-Alzheimers-Disease-Conference-CTAD24-in-Madrid-Spain/default.aspx"
X Link 2024-10-29T12:01Z [----] followers, [---] engagements

"ALS affects nerve cells in the brain and spinal cord. Coya is developing COYA [---] to potentially enhance the function of regulatory T cells (Tregs) to target #neurodegenerative diseases like ALS. Learn more from @ALSassociation: #EndALS #Research https://ow.ly/nh6M50Ubix2 https://ow.ly/nh6M50Ubix2"
X Link 2024-12-11T13:40Z [----] followers, [---] engagements

"GLP-1s are showing promise beyond their indications. Coya recently expanded our pipeline with COYA303 which combines COYA301 with GLP-1 receptor agonists. We're excited to see what [----] has in store for this combination biologic. #GLP1 #Ozempic #Wegovy https://www.medicalnewstoday.com/articles/glp-1-drugs-like-ozempic-may-protect-brain-health https://www.medicalnewstoday.com/articles/glp-1-drugs-like-ozempic-may-protect-brain-health"
X Link 2025-01-23T19:55Z [----] followers, [---] engagements

"Coya's first employee @FamilialALS VP of Operations and Patient Advocacy has been fighting for those suffering from #neurodegenerative diseases most of his life and he has a good reason - a genetic mutation he's inherited that is a marker for future FTD or ALS development. @Rice_Biz featured Daniel as a rising alumnus and his story Fighting Fate in their Spring issue. Read the full feature #EndALS #EndFTD https://business.rice.edu/magazine/features/fighting-fate https://business.rice.edu/magazine/features/fighting-fate"
X Link 2025-04-29T18:33Z [----] followers, [---] engagements

"#ICYMI Coya announced publication of a study with COYA [---] a combination of GLP-1 and low-dose IL-2 demonstrating synergistic enhancement of regulatory T cell function and protection against Treg apoptosis or cell death. Read the full publication: #GLP1 https://www.degruyterbrill.com/document/doi/10.1515/nipt-2025-0001/html https://www.degruyterbrill.com/document/doi/10.1515/nipt-2025-0001/html"
X Link 2025-05-21T15:50Z [----] followers, [---] engagements

"Coya CEO Arun Swaminathan recently joined@MikeKoelzer and @BizOfPharmPod to talk about negotiation leadership and why win-win deals matter in pharma. Check out the full podcast here or wherever you listen to your podcasts: $COYA #CoyaTherapeutics #Leadership https://www.bizofpharmpod.com/great-negotiation-means-everyone-wins-arun-swaminathan-mm-phd-pharm-sci-coya-theraeutics-ceo/ https://www.bizofpharmpod.com/great-negotiation-means-everyone-wins-arun-swaminathan-mm-phd-pharm-sci-coya-theraeutics-ceo/"
X Link 2025-05-29T12:40Z [----] followers, [---] engagements

"#ICYMI Our CEO Arun Swaminathan recently presented at the @HCWCO Annual BioConnect Investor Conference in May about the latest with the Company and our therapeutics. You can listen to the full presentation by following this link to the webcast: $COYA #CoyaTherapeutics https://bit.ly/4jzqQeh https://bit.ly/4jzqQeh https://bit.ly/4jzqQeh https://bit.ly/4jzqQeh"
X Link 2025-06-18T13:00Z [----] followers, [---] engagements

"Team Coya will be in Dallas on August 11-14 attending #ALSNexus hosted by the @alsassociation. We look forward to engaging in stimulating discussions and networking with leaders changing the future of #ALS Send us a note at info@coyatherapeutics.com if you would like to connect For more information: $COYA #EndALS https://www.als.org/als-nexus https://www.als.org/als-nexus"
X Link 2025-08-08T14:59Z [----] followers, [---] engagements

"Listen to this exciting discussion on the Business of Biotech podcast with our CEO Arun Swaminathan alongside Milan Kalawadia from @drreddys where they discuss our companys partnership to develop our lead asset COYA [---] a novel dual-mechanism immunotherapy for the treatment of #ALS. Watch the full segment here: $COYA #EndALS https://www.youtube.com/watchv=cg_NQliW_e4&list=PLFXsCNKV78rWNPmqIA8b2dKYLPYYv28wb https://www.youtube.com/watchv=cg_NQliW_e4&list=PLFXsCNKV78rWNPmqIA8b2dKYLPYYv28wb"
X Link 2025-08-18T14:52Z [----] followers, [---] engagements

"Coya Therapeutics announced this morning a statistically significant improvement of inflammatory blood markers in patients with Alzheimers disease following monthly dosing with Low-Dose IL-2. Read more in Coya's latest PR: $COYA #Research https://ir.coyatherapeutics.com/news/news-details/2025/Coya-Therapeutics-Reports-Statistically-Significant-Improvement-of-Inflammatory-Blood-Markers-in-Patients-with-Alzheimers-Disease-Following-Monthly-Dosing-with-Low-Dose-IL-2-Further-Supporting-Clinical-Development/default.aspx"
X Link 2025-02-06T13:04Z [----] followers, [---] engagements

"Dr. Stanley Appel the head of Coya's Scientific Advisory Board was recognized by the @alsassociation. We are privileged to continue to work with Dr. Appel and his team to find therapeutic solutions to #EndALS. Read more: #ALS #Research #Legacy https://www.als.org/blog/legacy-hope-dr-stanley-appels-personal-journey-als-research-and-care https://www.als.org/blog/legacy-hope-dr-stanley-appels-personal-journey-als-research-and-care"
X Link 2025-02-12T16:10Z [----] followers, [---] engagements

"Dr. Leila Allen gave a talk last year where she spoke about her late fathers FTD diagnosis. We are committed alongside Dr. Allen to important research that helps us better understand diagnose and treat this disease. #EndFTD #Research https://www.theaftd.org/posts/1ftd-in-the-news/in-tedx-talk-neuroscientist-shares-her-fathers-ftd-story-and-her-hope-for-dementia-research-breakthroughs/ https://www.theaftd.org/posts/1ftd-in-the-news/in-tedx-talk-neuroscientist-shares-her-fathers-ftd-story-and-her-hope-for-dementia-research-breakthroughs/"
X Link 2025-02-19T13:55Z [----] followers, [---] engagements

"Coya CEO Arun Swaminathan recently joined the Bio Report Podcast with @dslevine to talk about the latest in Coya's science including COYA [---] an investigational biologic combination of COYA [---] and GLP-1 RAs for neurodegenerative and autoimmune diseases. Take a listen to the full podcast below or wherever you get your podcasts #CoyaTherapeutics #Research #GLP1 $COYA https://www.youtube.com/watchv=4wrBg8GKiOA https://www.youtube.com/watchv=4wrBg8GKiOA"
X Link 2025-02-19T14:55Z [----] followers, [---] engagements

"COYA [---] is a combination therapy that combines a low-dose IL-2 with CTLA4-Ig. Coya Therapeutics is dedicated to pioneering the research and development of therapies like COYA [---]. Learn more about Coya's science and technology here: $COYA https://coyatherapeutics.com/science-and-technology/ https://coyatherapeutics.com/science-and-technology/"
X Link 2025-04-16T14:30Z [----] followers, [---] engagements

"We are on the ground at #ALSNexus This event brings together researchers advocates industry leaders and people living with #ALS all working towards changing the future of ALS. At Coya we're proud to contribute to this mission and look forward to collaborating learning and driving progress alongside so many passionate individuals. If you're attending lets connect For more information: $COYA #EndALS @alsassociation https://www.als.org/als-nexus https://www.als.org/als-nexus"
X Link 2025-08-12T22:14Z [----] followers, [---] engagements

"Our CEO Arun Swaminathan Ph.D. was recently featured on the @Biotech2050Pod with host Alok Tayi. In this episode they explore Coyas science-driven approach to transforming care in #ALS the promise of immunomodulation and what it takes to move innovative therapies from concept to clinic always with patients and families at the center. Tune in to the full discussion to learn more about the work driving us forward: https://www.biotech2050.com/episodes/arun-swaminathan-coya-ceo-on-neuroinflammation-bd-strategy-amp-patient-driven-biotech"
X Link 2025-11-20T22:08Z [----] followers, [---] engagements

"Were honored to be named one of Houstons fastest-growing scaleup companies and a finalist for the [----] Houston Innovation Awards Scaleup of the Year. Thank you to @InnoMapHou and Laura Furr Mericas for highlighting the incredible momentum happening across Houstons innovation ecosystem and for recognizing Coya Therapeutics progress among such standout companies. For more details: #Neurodegenerative #Neuroscience #CNSHealth $COYA https://houston.innovationmap.com/fastest-growing-companies-in-houston-2674258053.html"
X Link 2025-11-24T17:50Z [----] followers, [---] engagements

"Our President and Chief Medical Officer Dr. Fred Grossman will be participating as a panelist at @CTADconference tomorrow at 3:10 PM PT in the upcoming roundtable: Charting the Path Forward for Combination Therapy in Alzheimers Disease: Challenges Considerations and Collaborative Solutions. #CTAD25 For more details: https://www.ctad-alzheimer.com/program https://www.ctad-alzheimer.com/program"
X Link 2025-12-01T20:06Z [----] followers, [---] engagements

"Grateful to Annabel Kartal-Allen and the @TrialsArena team for speaking with our President & CMO Dr. Fred Grossman and shining a spotlight on our work to advance Treg-based therapies for #ALS. Were excited about the progress of COYA [---] in its Phase II ALSTARS study and the potential to bring meaningful innovation to patients facing ALS. Read the article here: #EndALS #Tregs $COYA https://www.clinicaltrialsarena.com/news/coya-therapeutics-hopes-for-als-treg-approval-on-phase-ii-trial/cf-view"
X Link 2025-12-04T15:48Z [----] followers, [---] engagements

"Our CEO Arun Swaminathan Ph.D. was featured in a recent @BioSpace article by Annalee Armstrong examining whats next in Alzheimers drug development following Novo Nordisks GLP-1 trial results. As the field continues to evolve beyond single-target strategies Coya remains focused on advancing innovative immunomodulatory approaches that could help move the needle for patients with neurodegenerative diseases. Read the article here: $COYA #AlzheimersDisease #AD #Neurodegeneration #CombinationTherapy #GLP1"
X Link 2026-01-06T17:45Z [----] followers, [---] engagements

"Coya today announced the results of an investigator-initiated study of LD IL-2 and CTLA4-Ig demonstrating Treg enhancement and cognitive stability in frontotemporal dementia (#FTD) patients: CEO Arun Swaminathan said We believe these results suggest the potential for COYA-302 as a therapeutic option for patients with FTD. We look forward to advancing COYA-302 in a well-controlled phase [--] clinical trial in patients with FTD. For more details:"
X Link 2026-01-08T14:35Z [----] followers, [--] engagements

"Our CEO Arun Swaminathan Ph.D. was featured in a recent BioSpace article by Annalee Armstrong. As Arun shared this years #JPM26 offered a meaningful opportunity to focus on strategic partnerships supported by a stronger market outlook and growing momentum for M&A across the sector. Read the article here: #Biotech #Biopharma #Pharma $COYA https://www.biospace.com/business/at-jpm26-policy-and-politics-will-loom-large-for-pharma-as-biotech-sees-the-sun https://www.biospace.com/business/at-jpm26-policy-and-politics-will-loom-large-for-pharma-as-biotech-sees-the-sun"
X Link 2026-01-15T20:46Z [----] followers, [---] engagements

"Thank you to Kyle Umipig of @LongevityTech for covering our recent announcement of the FDAs acceptance of the IND application for COYA [---] enabling clinical evaluation of a novel immune-based approach to treating #FTD. Rather than targeting symptoms COYA [---] is designed to address underlying neuroinflammation by enhancing the anti-inflammatory function of regulatory T cells. Read the article here: #FrontotemporalDementia #Neurodegeneration $COYA https://longevity.technology/news/coya-advances-immune-based-therapy-for-early-dementia/"
X Link 2026-01-15T22:30Z [----] followers, [---] engagements

"Thank you @endpts for featuring our latest news about David Snyder joining as CFO and COO. Read more by Alex Hoffman @KathyW0NG and Derek Graf via here: #Leadership #Finance #Biotech #Health https://endpts.com/changes-in-high-ranking-execs-poised-to-deepen-at-karyopharm-tillman-gerngross-chaired-biotech-promotes-new-medical-chief-to-ceo/ https://endpts.com/changes-in-high-ranking-execs-poised-to-deepen-at-karyopharm-tillman-gerngross-chaired-biotech-promotes-new-medical-chief-to-ceo/"
X Link 2022-04-04T16:20Z [----] followers, [--] engagements

"#ICYMI Coya Therapeutics announced positive results yesterday of an investigator initiated double-blind study of low-dose IL-2 in Alzheimers Disease co-sponsored with @MethodistHosp @alzassociation @gatesfoundation and @NIHAging with support provided by Coya. The study strongly supports Coyas approach to address #neurodegenerative diseases and once-a-month dosing underscoring the importance of appropriate IL-2 dosing for maintaining Treg functionality and its associated effects on CSF biomarkers and cognitive outcomes. "Alireza Faridar M.D. lead investigator and neurologist at Houston"
X Link 2024-10-30T14:10Z [----] followers, [---] engagements

"Coya Therapeutics announces that as previously disclosed Arun Swaminathan Ph.D. has been promoted to Chief Executive Officer effective today November [--]. He brings a wealth of strategic business development operational and deal-making experience to help guide Coya in its next phase of corporate growth. Arun said: "We believe our combination therapeutic approach targeting neuroinflammation can unlock a new paradigm in neurodegenerative treatment. We are encouraged by data from the Phase [--] investigator-initiated trial in patients with mild to moderate Alzheimers disease treated with low-dose"
X Link 2024-11-01T12:22Z [----] followers, [---] engagements

"Coya Therapeutics announced this morning unaudited third quarter [----] financial results as well as a corporate update. Read more in the latest press release here: $COYA #CoyaTherapeutics https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-Provides-a-Corporate-Update-and-Reports-Unaudited-Third-Quarter-2024-Financial-Results/default.aspx https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-Provides-a-Corporate-Update-and-Reports-Unaudited-Third-Quarter-2024-Financial-Results/default.aspx"
X Link 2024-11-06T13:54Z [----] followers, [---] engagements

"Coya Therapeutics CEO Dr. Arun Swaminathan issued a letter to shareholders this morning to discuss his thoughts on Coya and the future of the company heading into [----]. Read more in our latest press release: $COYA #CoyaTherapeutics #EndALS #EndFTD https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-CEO-Dr.-Arun-Swaminathan-Issues-Letter-to-Stockholders/default.aspx https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-CEO-Dr.-Arun-Swaminathan-Issues-Letter-to-Stockholders/default.aspx"
X Link 2024-11-19T13:19Z [----] followers, [---] engagements

"COYA [---] is a therapy that combines two different biologics low-dose IL-2 and CTLA-4 Ig. Complex diseases demand complex treatment solutions. Learn more from @BioProcessOL: $COYA #CoyaTherapeutics #CombinationBiologics https://www.bioprocessonline.com/doc/coya-therapeutics-on-developing-a-combination-biologic-0001 https://www.bioprocessonline.com/doc/coya-therapeutics-on-developing-a-combination-biologic-0001"
X Link 2024-11-21T14:25Z [----] followers, [---] engagements

"Coya Therapeutics announced today participation in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference on Tuesday December [--]. Get all the details in our latest press release: #CoyaTherapeutics $COYA #FiresideChat https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-to-Participate-in-a-Fireside-Chat-at-the-7th-Annual-Evercore-HealthCONx-Conference/default.aspx https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-to-Participate-in-a-Fireside-Chat-at-the-7th-Annual-Evercore-HealthCONx-Conference/default.aspx"
X Link 2024-11-25T13:33Z [----] followers, [---] engagements

"Coya CEO Arun Swaminathan recently sat down with @InnoMapHou to discuss the CEO transition his background and his plans for the company. Read the full Q&A here: #CoyaTherapeutics $COYA https://houston.innovationmap.com/coya-therapeutics-arun-swaminathan-ceo-2670009696.html https://houston.innovationmap.com/coya-therapeutics-arun-swaminathan-ceo-2670009696.html"
X Link 2024-11-27T15:41Z [----] followers, [---] engagements

"Coya Therapeutics announced today that five of eight patients have been enrolled in the investigator-initiated academic study of LD IL-2 + CTLA4-Ig combination in patients with Frontotemporal Dementia (FTD). The study is being conducted by Drs. Stanley Appel and Alireza Faridar at @MethodistHosp. Topline results of the study will be leveraged to inform and finalize the planned trial design of a Company-sponsored randomized double-blinded Phase [--] trial of COYA [---] in patients with FTD. Read more in our latest press release: $COYA #CoyaTherapeutics #Research"
X Link 2024-12-18T13:24Z [----] followers, [---] engagements

"Coya Therapeutics wishes you a happy New Year We are thrilled to continue our work for the treatment of neurodegenerative diseases like ALS and FTD. [----] will be a big year for our programs and we're excited for what's to come #CoyaTherapeutics #NewYear $COYA"
X Link 2025-01-03T13:45Z [----] followers, [---] engagements

"Coya Therapeutics announced today that COYA [---] a combination of COYA [---] and GLP-1 RA the mechanism behind therapeutics like Ozempic and Wegovy has shown promising anti-inflammatory effects in a preclinical study by enhancing regulatory Treg suppressive function and limiting inflammatory cellular responses. Read more in our latest press release: #CoyaTherapeutics #GLP1 #Ozempic #Wegovy #Treg"
X Link 2025-01-21T13:22Z [----] followers, [---] engagements

"Coya CEO Arun Swaminathan recently joined @PharmaVoice to talk about his taking over the role at the end of last year as well as the road ahead for the company. Take a read through the full article here: #CoyaTherapeutics $COYA #Leadership #Research https://www.pharmavoice.com/news/coya-therapeutics-ceo-arun-swaminathan/738309/ https://www.pharmavoice.com/news/coya-therapeutics-ceo-arun-swaminathan/738309/"
X Link 2025-01-27T18:30Z [----] followers, [---] engagements

"A recent Harvard research study published in Science Immunology demonstrated that Tregs can safeguard brain health and memory formation. Coya Therapeutics is currently developing Treg modulating therapies to address neurodegenerative diseases like ALS FTD and more. Read more about the research here: #Tregs #CoyaTherapeutics #EndALS #EndFTD $COYA https://hms.harvard.edu/news/regulatory-t-cells-found-safeguard-brain-health-memory-formation https://hms.harvard.edu/news/regulatory-t-cells-found-safeguard-brain-health-memory-formation"
X Link 2025-02-03T13:45Z [----] followers, [---] engagements

"Coya Therapeutics will present virtually on Feb. [--] at the Oppenheimer 35th Healthcare Life Sciences Conference. An archived version of the webcast will be available following the event on our website. Read more here: $COYA #CoyaTherapeutics #Tregs https://ir.coyatherapeutics.com/news/news-details/2025/Coya-Therapeutics-to-Present-at-the-Oppenheimer-35th-Annual-Healthcare-Life-Sciences-Conference/default.aspx https://ir.coyatherapeutics.com/news/news-details/2025/Coya-Therapeutics-to-Present-at-the-Oppenheimer-35th-Annual-Healthcare-Life-Sciences-Conference/default.aspx"
X Link 2025-02-04T13:18Z [----] followers, [---] engagements

"Coya Therapeutics will participate in a KOL call hosted by BTIG to discuss the potential treatment of Alzheimers Disease using GLP-1 agonists and combinations on Feb. [--]. Read more in our latest press release: $COYA #CoyaTherapeutics #KOL #Event https://ir.coyatherapeutics.com/news/news-details/2025/Coya-Therapeutics-to-Participate-in-KOL-Call-Hosted-by-BTIG-to-Discuss-the-Potential-Treatment-of-Alzheimers-Disease-Using-GLP-1-Agonists-and-Combinations/default.aspx"
X Link 2025-02-25T13:18Z [----] followers, [---] engagements

"Catch our CEO Arun Swaminathan on the latest episode of theConversations Life Science Leaders Aren't Having podcast with host Jeff Harmon. He discusses his journey from scientist to CEO and the important work Coya Therapeutics is focused on: #CoyaTherapeutics #Neurodegenerative #Biotech https://twitter.com/i/web/status/1902008833188212914 https://open.spotify.com/episode/05ViYjsWDMHPiDbpeogU7K https://twitter.com/i/web/status/1902008833188212914 https://open.spotify.com/episode/05ViYjsWDMHPiDbpeogU7K"
X Link 2025-03-18T14:46Z [----] followers, [---] engagements

"Coya Therapeutics provided a corporate update today and announced our financial results for the year ended December [--] [----]. Read the release here: $COYA #CoyaTherapeutics https://ir.coyatherapeutics.com/news/news-details/2025/Coya-Therapeutics-Provides-a-Corporate-Update-and-Reports-Fiscal-2024-Financial-Results/default.aspx https://ir.coyatherapeutics.com/news/news-details/2025/Coya-Therapeutics-Provides-a-Corporate-Update-and-Reports-Fiscal-2024-Financial-Results/default.aspx"
X Link 2025-03-18T14:57Z [----] followers, [---] engagements

"Coya CEO Arun Swaminathan recently joined Ayesha Rashid and the XTalks Podcast to talk Treg therapies targeting neurodegenerative diseases. Tune into the episode below or wherever you get your podcasts to learn more about the pipeline: #CoyaTherapeutics https://xtalks.com/innovating-treg-therapies-for-als-and-alzheimers-with-coya-therapeutics-ceo-dr-arun-swaminathan-episode-200/utm_source=social&utm_medium=podcast&utm_campaign=200"
X Link 2025-03-24T13:10Z [----] followers, [---] engagements

"Coya Therapeutics announced today progress from an academic supported first-in-class Treg-derived exosome program. Read more in our latest press release: #CoyaTherapeutics #Exosome #Research https://ir.coyatherapeutics.com/news/news-details/2025/Coya-Therapeutics-Reports-Progress-from-an-Academic-Supported-First-in-Class-Treg-derived-Exosome-Program/default.aspx https://ir.coyatherapeutics.com/news/news-details/2025/Coya-Therapeutics-Reports-Progress-from-an-Academic-Supported-First-in-Class-Treg-derived-Exosome-Program/default.aspx"
X Link 2025-03-26T12:28Z [----] followers, [---] engagements

"Navigating insurance with #ALS can be tough leading to the ALS Association launching a new resource to help. Coya Therapeutics is dedicated to the development of therapies to enhance Tregs for the treatment of conditions like ALS. Learn more: #EndAL https://www.als.org/blog/fight-coverage-you-deserve https://www.als.org/blog/fight-coverage-you-deserve"
X Link 2025-03-31T16:25Z [----] followers, [---] engagements

"Coya Therapeutics announced this morning the selection of previously announced data to be presented at the ADPD [----] conference in Vienna on April [--]. Read more in our latest press release: $COYA #CoyaTherapeutics #Research https://ow.ly/BMCh50VseWZ https://ow.ly/BMCh50VseWZ"
X Link 2025-04-01T12:18Z [----] followers, [---] engagements

"Coya Therapeuetics announces publication of COYA [---] study results demonstrating synergistic enhancement of regulatory T Cell function and protection against treg apoptosis. Read more in our latest press release: $COYA #CoyaTherapeutics #GLP1 https://ow.ly/5lMQ50VEIJI https://ow.ly/5lMQ50VEIJI"
X Link 2025-04-21T13:52Z [----] followers, [---] engagements

"Coya Therapeutics announces positive interim results of an investigator-initiated open label study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in five patients with FTD. Read more in our latest press release: $COYA #CoyaTherapeutics #EndFTD https://ow.ly/ERVx50VH11Y https://ow.ly/ERVx50VH11Y"
X Link 2025-04-24T12:19Z [----] followers, [---] engagements

"Coya Therapeutics announces it will participate in two upcoming conferences in May 2025: the D. Boral Capital Inaugural Global Conference and the Mizuho Neuro & Opthalmology Summit. Full details available in our latest release: $COYA #CoyaTherapeutics https://ow.ly/qqkP50VPaCt https://ow.ly/qqkP50VPaCt"
X Link 2025-05-08T12:28Z [----] followers, [---] engagements

"Coya Therapeutics announces this morning first quarter financial results and provides a corporate update. Read more in our latest press release: $COYA #CoyaTherapeutics https://ow.ly/upnS50VRIgw https://ow.ly/upnS50VRIgw"
X Link 2025-05-13T12:28Z [----] followers, [---] engagements

"Coya Therapeutics announces it will participate in the H.C. Wainwright 3rd Annual BioConnect Conference being held in New York City on Tuesday May [--]. Read more in our latest press release: $COYA #CoyaTherapeutics #HCWCO https://ow.ly/vYEL50VTYkH https://ow.ly/vYEL50VTYkH"
X Link 2025-05-16T14:59Z [----] followers, [---] engagements

"Coya Therapeutics announces this morning the issuance of a U.S. patent relevant to its investigational ready-to-use liquid formulation of IL-2 strengthening its strategic and business development optionality. Read more in our latest press release: #CoyaTherapeutics $COYA https://ir.coyatherapeutics.com/news/news-details/2025/Coya-Therapeutics-Announces-Issuance-of-New-U-S--Patent-Protecting-Methods-of-Producing-Recombinant-Human-rh-Interleukin-2-aldesleukin-Liquid-Formulations/default.aspx"
X Link 2025-06-02T12:33Z [----] followers, [---] engagements

"Coya Therapeutics CEO Arun Swaminathan recently joined Bryce McNallie on the @McnallieM Podcast to discuss the latest with the company and the progress being made on our therapeutics. Thanks for having us #CoyaTherapeutics $COYA https://youtu.be/IKdQqWEgPys https://youtu.be/IKdQqWEgPys"
X Link 2025-06-04T12:45Z [----] followers, [---] engagements

"CEO Arun Swaminathan was featured this morning in @PharmaVoice discussing important candidates that could shake up the #ALS treatment landscape including COYA [---]. Coya Therapeutics is focused on enhancing the power of Tregs to better treat #neurodegenerative diseases. Read the full article here: #CoyaTherapeutics #EndALS https://www.pharmavoice.com/news/als-drug-approaches-coya-amylyx/751540/ https://www.pharmavoice.com/news/als-drug-approaches-coya-amylyx/751540/"
X Link 2025-06-25T12:41Z [----] followers, [---] engagements

"Living with #ALS is challenging and current treatments only offer limited slowing not a cure. Patients need and deserve a better quality of life. Coya Therapeutics is researching the power of #Tregs for #neurodegenerative diseases like ALS. Learn more from @alsassociation: $COYA #BrainHealthAwareness http://als.org https://twitter.com/i/web/status/1938213189327438058 http://als.org https://twitter.com/i/web/status/1938213189327438058"
X Link 2025-06-26T12:30Z [----] followers, [---] engagements

"Coya Therapeutics is proud to announce our new Vice President of Clinical Development Mark Gordon A board-certified neurologist and fellowship-trained specialist in Movement Disorders he brings extensive experience across academic clinical research and industry settings to our leadership team. Mark has led more than [--] clinical trials across the clinical program pathway from phase 2-4 and has authored more than [---] peer-reviewed publications seven book chapters and over [---] scientific presentations focused on clinical outcomes biomarkers and therapeutics. At Coya Mark will lead clinical"
X Link 2025-07-31T14:40Z [----] followers, [---] engagements

"Coya Therapeutics announced 2Q25 financial results and provides a corporate update. Read more in our latest press release: $COYA https://www.prnewswire.com/news-releases/coya-therapeutics-reports-second-quarter-financial-results-and-provides-a-corporate-update-302526910.htmltc=eml_cleartime https://www.prnewswire.com/news-releases/coya-therapeutics-reports-second-quarter-financial-results-and-provides-a-corporate-update-302526910.htmltc=eml_cleartime"
X Link 2025-08-12T13:22Z [----] followers, [---] engagements

"Coya Therapeutics has announced that the FDA has accepted its Investigational New Drug (IND) application for COYA 302s Phase [--] Trial in #ALS. This milestone marks a critical step forward as we advance our mission of delivering hope and new options to those living with ALS. $COYA https://www.prnewswire.com/news-releases/coya-therapeutics-announces-fda-acceptance-of-investigational-new-drug-ind-application-for-coya-302-for-the-treatment-of-amyotrophic-lateral-sclerosis-als-302537194.htmltc=eml_cleartime"
X Link 2025-08-25T12:11Z [----] followers, [----] engagements

"Coya Therapeutics announced today that its COYA [---] ALS Trial has been accepted by @NEALSConsortium as a NEALS-Affiliated Trial. As an affiliated study the COYA [---] Phase [--] clinical trial will benefit from broad support across NEALS' institutional and community networks enhancing operational execution and maximizing clinical impact. The COYA [---] study will be presented during the NEALS Educational Webinar on September [--] [----]. For more information: $COYA #EndALS #ALS"
X Link 2025-09-04T17:36Z [----] followers, [---] engagements

"Breakthrough Alert: Coya Therapeutics COYA-303 (Low-dose IL-2 + GLP-1 agonist) shows promise in preclinical studies: reduced neuroinflammation boosted Treg function & survival lower pro-inflammatory cells. More cohorts underway & full data coming soon. Is this the multi-target strategy Alzheimers needs #Neurodegeneration #AlzheimersResearch Read more in: https://sg.finance.yahoo.com/news/exclusive-coya-therapeutics-investigational-combination-114552814.htmlutm_source=chatgpt.com&guccounter=1"
X Link 2025-09-16T12:51Z [----] followers, [---] engagements

"News Alert Today Coya Therapeutics has announced the launch of the ALSTARS Trial a Phase [--] Clinical Study to Assess the Efficacy and Safety of COYA [---] in Amyotrophic Lateral Sclerosis (#ALS). The ALSTARS Trial is a randomized multi-center double-blind placebo-controlled study of COYA [---] in people with ALS. Patients completing the initial 24-week treatment will be invited to participate in a 24-week blinded extension period during which all participants will receive COYA [---]. Read here for more details on the trial: $COYA #EndALS"
X Link 2025-09-22T14:36Z [----] followers, [---] engagements

"Our CEO Arun Swaminathan represented Coya Therapeutics yesterday at #BioFuture2025 as a panelist in Rewiring Minds: Breakthroughs in Brain & CNS Health. As we continue our work advancing therapies like COYA [---] it was a meaningful opportunity to share Coyas perspective on the critical role of regulatory T cell modulation in #neurodegenerative disease. Thank you to the organizers and fellow panelists for the engaging and insightful dialogue. #CNSHealth #Neuroscience $COYA #ALS #EndALS #Innovation https://twitter.com/i/web/status/1978177268481438048"
X Link 2025-10-14T19:13Z [----] followers, [---] engagements

"This past weekend our VP of Operations and Patient Advocacy @FamilialALS proudly represented Coya Therapeutics at the Walk to Defeat ALS Seattle standing in solidarity with patients families and advocates united in the fight to #EndALS. Being present in the community listening to those living with #ALS and walking alongside them is core to why we do what we do. Were honored to be part of a movement fueled by resilience hope and determination and we remain focused on advancing therapies like COYA [---] to make a lasting impact. For more about our work: #ALSResearch #ALSCommunity $COYA"
X Link 2025-10-16T15:48Z [----] followers, [---] engagements

"Thank you to @TheScientistLLC for speaking with our President & CMO Fred Grossman DO FAPA in this insightful Q&A exploring the science behind COYA [---] and its potential to change the trajectory of ALS. In this Innovation Spotlight Dr. Grossman discusses how Coya Therapeutics is addressing immune dysregulation in ALS through COYA [---] our investigational biologic designed to restore regulatory T cell (Treg) function and rebalance the immune system. Read the article here: https://www.the-scientist.com/reprogramming-immunity-to-treat-als-73585 https://twitter.com/i/web/status/1983558597301678346"
X Link 2025-10-29T15:36Z [----] followers, [---] engagements

"Coya Therapeutics congratulates our Scientific Advisory Board member Dr. Shimon Sakaguchi MD Ph.D. on his continued groundbreaking work following his receipt of the [----] Nobel Prize in Physiology or Medicine. Dr. Sakaguchis pioneering research on immune tolerance continues to inspire our mission at Coya: to develop therapies that restore Treg function and rebalance the immune system in ALS and other neurodegenerative diseases. We are honored to have his insight and leadership guiding our scientific efforts. Read the article here:"
X Link 2025-10-31T17:30Z [----] followers, [---] engagements

"Today Coya Therapeutics announced that its combination low-dose IL-2/GLP-1 receptor agonist (COYA 303) significantly reduced peripheral pro-inflammatory cell expansion enhanced regulatory T cell function attenuated CNS inflammation and shifted macrophages to an anti-inflammatory phenotype compared to controls. COYA [---] has the potential for treating inflammation-driven diseases like Alzheimer's Disease and other #neurodegenerative and #autoimmune diseases. For more details: #AlzheimersDisease #AD $COYA"
X Link 2025-11-04T17:00Z [----] followers, [---] engagements

"Coya Therapeutics announced 2Q25 financial results and provides a corporate update. Read more in our latest press release: #EndALS #ALSResearch #Neurodegenerative #Neuroscience #CNSHealth $COYA https://ir.coyatherapeutics.com/news/news-details/2025/Coya-Therapeutics-Announces-That-Its-Combination-LD-IL-2GLP-1-RA-Candidate-COYA-303-Demonstrated-Potent-Systemic-and-Brain-Anti-Inflammatory-Efficacy-In-Vivo/default.aspx"
X Link 2025-11-12T16:46Z [----] followers, [---] engagements

"Coyas senior management will be participating in two conferences on Tuesday December 2: - 8th Annual Evercore Healthcare Conference - 18th Clinical Trials on Alzheimers Conference (#CTAD25) See here for more details: #AlzheimersDisease #AD $COYA https://ir.coyatherapeutics.com/news/news-details/2025/Coya-Therapeutics-to-Participate-in-Upcoming-Investor-Relations-and-Clinical-Trials-Conferences/default.aspx https://ir.coyatherapeutics.com/news/news-details/2025/Coya-Therapeutics-to-Participate-in-Upcoming-Investor-Relations-and-Clinical-Trials-Conferences/default.aspx"
X Link 2025-11-25T18:36Z [----] followers, [---] engagements

"Coya Therapeutics is in San Francisco for #JPM26 connecting with industry leaders amid renewed optimism across biotech. With momentum building around strategic partnerships and innovation in #neurodegenerative disease this years conversations are focused on collaboration and long-term value creation. #Biotech #Biopharma #Pharma $COYA https://twitter.com/i/web/status/2011501607532323217 https://twitter.com/i/web/status/2011501607532323217"
X Link 2026-01-14T18:12Z [----] followers, [---] engagements

"Were excited to be attending the 16th Annual ALS Network Research Summit this week in Pasadena Looking forward to connecting with fellow researchers clinicians and advocates as we work together toward new insights and advancements in #ALS research. For more: #EndALS #ALSResearch #neurodegenerative $COYA https://sites.google.com/alsnetwork.org/16thalsresearchsummit/home https://sites.google.com/alsnetwork.org/16thalsresearchsummit/home"
X Link 2026-01-21T18:10Z [----] followers, [---] engagements

"Coya was proud to attend the 16th Annual ALS Network Research Summit joining researchers clinicians and advocates dedicated to advancing #ALS research. @youralsnetwork The summit sparked thoughtful discussions and valuable connections reinforcing the importance of collaboration as we work toward meaningful progress for the ALS community. Were grateful to be part of these important conversations and look forward to building on the momentum ahead. For more: #ALSResearch #EndALS #Biotech $COYA https://sites.google.com/alsnetwork.org/16thalsresearchsummit/home"
X Link 2026-01-28T17:55Z [----] followers, [---] engagements

"- Dr. Reddys Laboratories Inc. a subsidiary of our current strategic collaborator makes a $10 million investment - Greenlight Capital an existing institutional shareholder is the only other investor participating in the offering with a $1.1 million investment Coya intends to use the net proceeds primarily to accelerate tech transfer and scale-up manufacturing activities for low dose IL-2 to support commercial readiness of COYA [---] the companys treatment for #ALS. For more details: $COYA"
X Link 2026-01-30T13:55Z [----] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing